PANOBINOSTAT

作品数：9被引量：3H指数：1
导出分析报告
相关领域：医药卫生更多>>
相关作者：齐文秀吴福群严华林江雪杰王治香更多>>
相关机构：广州医科大学吉林大学天津市永久医院南方医科大学南方医院更多>>
相关期刊：《药学进展》《Acta Pharmacologica Sinica》《Journal of Pharmacy and Pharmacology》《天津药学》更多>>
相关基金：国家自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-9
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
《Acta Pharmacologica Sinica》2024年第4期867-878,共12页Ting-ting Lin Wei Xiong Gui-hua Chen Yang He Li Long Xin-fu Gao Jia-lin Zhou Wen-wen Lv Yong-zhuo Huang 
supported by the National Key Research and Development Program of China(2021YFC2400600,2021YFE0103100);NFSC(81925035);Department of Science and Technology of Guangdong Province(High-level new R&D institute 2019B090904008,High-level Innovative Research Institute 2021B0909050003);the Scientific and Technological Innovation Leading Talent Project in Zhongshan City(LJ2021001);the Scientific Research and Innovation Team Project in Zhongshan City(CXTD2022011);and Research Foundation of Binzhou Medical University(BY2019KJ03).
Osimertinib (Osi) is widely used as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, the majority of patients treated with Osi eventually relapse within a year. The mechanism...
关键词：osimertinib resistance targeted drug delivery liposomes PANOBINOSTAT tumor-associated macrophage combination therapy 
ABCB1介导HDAC非选择性抑制剂panobinostat耐药的机制研究
《天津药学》2022年第4期12-19,共8页窦永海 高晓丽 
目的:探究ABCB1介导非选择性HDAC抑制剂panobinostat(PBST)在肿瘤细胞中耐药的机制。方法:以KB-3-1、SW620、HEK293/pcDNA3.1以及其对应的耐药细胞株KB-C2、SW620/Ad300、HEK293/ABCB1细胞为研究对象,利用MTT法评价panobinostat对上述...
关键词：PANOBINOSTAT 肿瘤耐药 ABC转运蛋白B1亚家族 药物蓄积 
Al-Akidi Therapeutic Protocol for Severe Infections Associated with Covid-19:Potential and Effective Treatment by Levofloxacin and Vitamin D3 and Zinc(Part 1)
《Journal of Pharmacy and Pharmacology》2022年第4期105-119,共15页Shakir Mahmood Alwan 
The author acknowledges the help and support of Dr.Sabah J.Saleh(The National Center for Quality Control and Research,Ministry of Health(Iraq))and Ameer H.Khadem(Department of Pharmaceutical Chemistry,College of Pharmacy,Al-Bayan University).
Background:The emergence of Coronavirus SARS-CoV-2 evoked an unprecedented threat globally.Ever since the spread of this pandemic research and clinical trials have concentrated on the repurposing of already exciting F...
关键词：Covid-19 LEVOFLOXACIN MOXIFLOXACIN ACE2 DOCKING PROTOCOL viral enzymes 3CL pro-1 Camostat PANOBINOSTAT Oseltamivir acid 
Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona被引量：3
《Acta Pharmaceutica Sinica B》2022年第4期2057-2073,共17页Yang He Yuefei Fang Meng Zhang Yuge Zhao Bin Tu Mingjie Shi Bahtiyor Muhitdinov Akmal Asrorov Qin Xu Yongzhuo Huang 
This work was supported by National Special Project for Significant Drugs Development(2018ZX09711002-010-002,China);National Natural Science Foundation of China(NSFC)(81925035,82050410361,and 81521005,China);Shanghai Collaborative Innovation Group(Early diagnosis and precise treatment of hemangiomas and vascular malformations,SSMU-ZDCX20180701,China);Shanghai Sci-Tech Innovation Action Plan(19431903100,China);Chinese Academy of Sciences(CAS)PIFI Fellowship(2019PB0076,2020PB0094,China);Belt&Road Young Scientist Award(Shanghai,18430740800,China).
There is a close connection between epigenetic regulation,cancer metabolism,and immunology.The combination of epigenetic therapy and immunotherapy provides a promising avenue for cancer management.As an epigenetic reg...
关键词：Tumor immune microenvironment Tumor-associated macrophage Epigenetic therapy Immune checkpoint Angiogenesis PANOBINOSTAT JQ1 LIPOSOME 
Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
《Cancer Drug Resistance》2021年第4期888-902,共15页Tiewei Cheng Kendall Kiser Leslie Grasse Lakesla Iles Geoffrey Bartholomeusz Felipe Samaniego Robert Z.Orlowski Joya Chandra 
Relevant to this study,Chandra J has received research support from Karus Pharmaceuticals and Novartis Pharmaceuticals;Orlowski RZ would like to acknowledge support from the National Cancer Institute(R01s CA184464 and CA194264);the Leukemia&Lymphoma Society Specialized Center of Research(SCOR-12206-17),and Dr.Miriam and Sheldon G.Adelson Research Foundation.
Aim:Multiple myeloma(MM)is a hematological malignancy of antibody-producing mature B cells or plasma cells.The proteasome inhibitor,bortezomib,was the first-in-class compound to be FDA approved for MM and is frequentl...
关键词：Histone deacetylase bortezomib resistance selective HDAC inhibitors HDAC6 HDAC7 
Panobinostat改善SD大鼠蛛网膜下腔出血后早期脑损伤的观察
《中国基层医药》2019年第9期1092-1096,共5页张加星 张业斌 吴力强 
目的观察在SD大鼠蛛网膜下腔出血动物模型中,Panobinostat抑制HDAC(LBH589)对早期脑损伤的作用。方法SD大鼠按随机数字表法分为假手术组(10只)、出血组(10只)、出血+Vehicle组(20只),出血+Panobinostat注射组和药物注射组(20只),于SAH...
关键词：蛛网膜下腔出血 脑损伤 Panobinostat(LBH589) 组蛋白去乙酰化酶(HDAC)/酶抑制剂 神经元 细胞凋亡 乙酰化作用 动物 
美国FDA批准抗肿瘤药Panobinostat上市
《中国执业药师》2015年第5期43-43,共1页
美国FDA于2015年2月23日批准诺华（Novartis）公司的Panobinostat（参考译名：帕比司他,商品名：Farydak）胶囊上市,与硼替佐米及地塞米松合用于治疗至少接受过2种疗法（包括硼替佐米及1种免疫抑制药）治疗的多发性骨髓瘤患者。Panobino...
关键词：美国FDA FDA批准 抗肿瘤药 上市 组蛋白去乙酰化酶 免疫抑制药 多发性骨髓瘤 硼替佐米 
Panobinostat可显著改善多发性骨髓瘤患者的无进展生存期
《中国执业药师》2014年第8期9-9,共1页
美国诺华（ Novartis ）公司于2014年6月2日宣布，其在研药物 Panobinostat （参考译名：帕比司他，曾用名：LBH589）与硼替佐米、地塞米松合用于多发性骨髓瘤患者的芋期临床试验达首要终末指标。本项试验结果于第50届美国临床肿瘤学会...
关键词：多发性骨髓瘤 无进展生存期 患者 美国临床肿瘤学会 临床试验 硼替佐米 地塞米松 ASCO 
抗癌药帕比司他
《药学进展》2007年第9期430-430,共1页
关键词：帕比司他 PANOBINOSTAT 抗癌药 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部